The phase I Dual ErbB Inhibition in Oesophago-gastric Cancer (DEBIOC) clinical trial assessed the efficacy of a small-molecule inhibitor with equipotent activity to EGFR, HER2 and HER3 (AZD8931) in combination with Xelox.17 This evidence concerns the gene EGFR and gastric cancer.